IJFANS INTERNATIONAL JOURNAL OF FOOD AND NUTRITIONAL SCIENCES
ISSN PRINT 2319 1775 Online 2320 7876

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 11, Nov 2022

A Brief Description on Mucormycosis

Mayur Porwal, Associate Professor,
Department of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India
Email Id- mayur.porwal1!gmail.com

ABSTRACT: Mucormycosis is an angio-invasive infection caused by the Mucorales fungus. Although it is an uncommon illness, it is becoming more common among immunocompromised individuals. Rhino-orbitocerebral, cutaneous, disseminated, gastrointestinal, and pulmonary forms may all be found. Despite the intensive therapy, there is an overall higher death rate. The primary goal and objective of this study were to provide an overview of Mucormycosis and its etiopathogenesis, as well as to discuss the fatality of rhinocerebral Mucormycosis and current advancements in diagnostic and therapeutic techniques. The presence of sporangiophores and rhizoid-like structures in his illustrations of the etiologic agent led to the conclusion that the infection was most likely caused by Lichtheimia corymbifera. More instances have been identified throughout time, and the disease's prevalence has risen.

KEYWORDS: Fungal, Illness, Infection, Mucorales, Mucormycosis.

1. INTRODUCTION

Mucormycosis is an angioinvasive fungal infection caused by Mucorales fungus. It is categorized as rhinocerebral, pulmonary, cutaneous, gastrointestinal, disseminated, or other, according on the clinical presentation, which includes unusual rare types such as endocarditis, osteomyelitis, peritonitis, renal, and so on. The illness was originally reported in 1876 by Fürbinger in Germany, who described a patient who died of cancer and had a hemorrhagic infarct in the right lung with fungal hyphae and a few sporangia. Arnold Paltauf described the first case of disseminated mucormycosis in 1885, calling it "Mycosis mucorina."

R.D. Baker, an American pathologist, created the name Mucormycosis. Zygomycosis is another name for it. It's a sneaky fungal illness spread by members of the Mucorales and zygomycotic families. Mucormycotina are saprobes that may be found in rotting waste or soil. Mucorales infections are classified according to how quickly they develop[1]–[5].

1.1 History:

The first instance of Mucormycosis was recorded in 1885 by German physician Paltauf, who named it Mycosis Mucorina. Mucormycosis became more common in immune compromised people in the 1980s and 1990s. According to the prevalence rate, a research conducted in France found that amplification occurs at a rate of 7.4 percent each year. Mucorales infection has been documented to occur all over the world, with the potential of seasonal fluctuation.

1.2 Etiopathogenesis:

Mucorales attack deep tissues by ingesting or inhaling spores, as well as injecting spores into the skin. The initial line of defense in a healthy host is capable of killing spores through oxidative metabolites and cationic peptides as soon as the spores enter lung or skin tissues. Uncontrolled diabetes mellitus, particularly ketoacidosis, steroid use, extremes of age, neutropenia; particularly in haematological malignancy, AIDS, renal insufficiency, organ or stem cell transplantation, iron overload, skin trauma, broad-spectrum antibiotics, intravenous drug abuse, prophylactic voriconazole for aspergillosis, and malnutrition are all risk factors.

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 11, Nov 2022

Because of the increased availability of micronutrients and the body's weakened defense mechanisms, mucormycosis develops as a damaging and possibly fatal disease in diabetes individuals. Several theories have been proposed, including I low serum inhibitory action against Rhizopus species, (ii) increased availability of iron for the pathogen at lower PH levels, and (iii) pulmonary macrophages of diabetics have a reduced capacity to prevent Rhizopus species germination. Rhizopus has a ketone reductase enzyme that enables it to enhance its glucose and acidic environment[6], [7].

1.3 Clinical Symptoms and Presentations:

There are two kinds of Mucormycosis infection in humans. 1 and 2 are superficial and visceral, while 2 and 3 are localized and disseminated. External ear, fingernails, and skin are examples of the superficial form. Pulmonary, gastric, and rhino cerebral kinds are examples of visceral forms. These spores may enter the body through the cutaneous or respiratory routes. (For example, spores may spread via dirty food or infected needles.)

1.4 Mucormycosis of the Rhinocerebral System:

Rhinocerebral Mucormycosis affects 33 to 50% of people. The aetiological agent is presumed to be Apophy-somyces elegans. An illness that starts in the paranasal sinuses, spreads to the brain through inhalation of spores, and eventually affects the sinuses, nose, and eyes. Its clinical manifestations begin with necrosis of the palate and sinuses, then progress to the orbit before affecting intracranial structures. Fever, blindness, exophthalmos, nosebleeds, facial paralysis, and indications of trigeminal nerve invasion are among the symptoms. Unsettled rhino-sinus mucormycosis will result in cavernous sinus thrombosis. A reddish-black nasal turbinate and septum, as well as a nasal discharge, may be observed. When the illness spreads to the cerebral vault, it causes blindness, lethargy, and convulsions, followed by death. According to Lanternier et al., this infection has a wide range of clinical manifestations, including an elevated frequency of primary cutaneous infection and a prognosis that is influenced by location. Mucor infection affects around 500 people in the United States each year. It has a lower prevalence than candidiasis or aspergillosis, which has a prevalence of 10 to 50 times. Mucormycosis may affect 2 to 3 percent of allogenic bone marrow transplant recipients.

1.5 Radiographic Characteristics:

Sinus opacification may be seen in combination with patchy effacement of the sinuses' bone walls. The “Black turbinate sign,” which refers to a region of non-enhancing mucosa on MRI, may be used to interpret mucor infection in cavernous sinus thrombophlebitis. Thickened mucosa or clouded sinuses, densely packed extraocular muscles, increased compactness of the orbital apex, proptosis, and optic nerve inflammation may be seen on a radiography or CT scan of the head. In the imaging of the lung in pulmonary Mucormycosis, the growth of micro nodules as well as an extra 10 nodules was discovered, which is consistent with Chamilos et al. results.

1.6 Histopathological Characteristics:

The afflicted tissue with lesions shows widespread necrosis with many big branching pale-staining, wide, flat non-septal hyphae branching at right or obtuse angles on inspection. In culture, sporangia that are round or ovoid are also common. Thin-walled hyphae (infrequently septae) with non-parallel sides ranging in diameter from 3 to 25m, branching erratically, and sometimes with

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 11, Nov 2022

bulbous hyphal swelling. Angio-invasion and infarction are found in necrotic tissue containing hyphae; in non-granulocytopenic circumstances, neutrophil infiltration and granuloma formation are seen; and in chronic infection, granuloma development is detected. The stainings of choice are Gomori Methamine Silver (Grocott) or Periodic - acid Schiff.

1.7 Method of Diagnosis:

Mucormycosis diagnosis involves a careful examination of clinical symptoms, magnetic resonance imaging modalities, early-stage computed tomography (CT), expert assessment of cytological and histological provision, best use of clinical microbiological method, and molecular detection. The detection of host variables is crucial in determining if a patient is at risk for invasive mucormycosis. The many laboratory procedures for identifying mucor include PAS stains, direct inspection, calcofluor, histological examination, Gomori methenamine silver stain, culture, molecular approaches, and fluorescent in situ hybridization. According to Kontoyiannis et al., one of the most difficult aspects of identifying mucormycosis is its indefinable clinical presentation and recurring occult spread, necessitating the use of a sensitive nonculture-based investigative technique. Tissue-based analysis is the gold standard analytic method for confirmation.

1.8 Differential Diagnosis:

Mucormycosis may be distinguished by the presence of maxillary sinus neoplasia, aspergillosis of the maxillary sinus, soft tissue infarction, soft tissue radio necrosis, and other deep fungal infections.

1.9 Treatment:

Rapid correct diagnosis, surgical debridement, and medication administration, as well as adjuvant application of hyperbaric oxygen, recombinant cytokines, or transfusion of granulocyte and prosthetic obturator, are all effective treatments for mucormycosis. According to Spellberg et al., presently available monotherapy has a significant death rate, particularly in haematology patients, and therefore the use of "combination treatment" for Mucormycosis is recommended.

AmB Dexycholate, Liposomal AmB (5-10mg/kg), AmB lipid complex, AmB colloidal dispersion, Posaconazole (400mg daily), and management of core disorders are all antifungal treatments. The use of a combination of caspofungin and lipid AmB, or a mixture of lipid AmB and Posaconazole as a second-line therapy, rather than Deferasirox, is recommended.

1.10 Rate of Morbidity and Prognosis:

The prognosis is usually determined by the severity of the illness's manifestations and the effectiveness of the therapy started in response to the condition. The survival rate for rhino-cerebral illness is approximately 75% in people without a systemic disease, 20% in individuals with other disorders, and 100% in patients with pulmonary disease.

The survival rate varies depending on the type of infection: rhino cerebral mucormycosis is 45 percent, focal cerebral mucormycosis is 33 percent, pulmonary forms are 36 percent, sinusitis without cerebral involvement is 87 percent, cutaneous isolated is 90 percent, disseminated disease is 16 percent, and gastro intestinal involvement is 10%. Patients with low baseline blood iron / ferritin concentrations, neutropenia, and malignant cases that are not linked with infection have a better survival rate.

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 11, Nov 2022

2. LITERATURE REVIEW

A. Skiada et al. discussed a review on the challenges and treatment of mucormycosis [8]. Mucormycosis is a difficult disease to diagnose and cure. The disease's prevalence seems to be rising. In high-income nations, hematological malignancies are the most frequent underlying illness, whereas in low-income countries, uncontrolled diabetes is the most common underlying condition. The clinical method to diagnosis is insufficiently sensitive and specific. Multiple (10) nodules and pleural effusion have been linked to pulmonary mucormycosis on radiology. The reverse halo sign is another finding on a computed tomography (CT) scan that seems to suggest the presence of mucormycosis. The foundations of diagnosis are microscopy (direct and on histology) and culture. Molecular tests may be used to detect or identify mucormycetes, and they might be suggested as useful add-on techniques to supplement standard diagnostic methods. Reversal or cessation of underlying predisposing factors, early delivery of active antifungal drugs at optimum dosages, full excision of all diseased tissues, and use of different adjuvant treatments are all part of a successful care strategy for mucormycosis. The addition of two newer azoles (posaconazole and isavuconazole) to liposomal amphotericin B, which remains the drug of choice for the initial antifungal treatment, according to the recently published ECIL-6 guidelines, as well as those published by ECMM/ESCMID, has slightly enriched our antifungal arsenal. Despite attempts to better understand the etiology of mucormycosis, early diagnosis, and vigorous treatment, the disease's death rate remains high.

N. Sipsas et al. discussed about the therapy of mucormycosis[9]. Despite the addition of mold-active agents (posaconazole and isavuconazole), as well as amphotericin B products, to our arsenal against mucormycosis, there are still many unknowns about how to treat this uncommon opportunistic infection because there are no data from prospective randomized clinical trials to guide treatment. We describe the current state of therapy choices in this mini-review. Mucormycosis management necessitates an individualized management plan that takes into account the net state of immunosuppression of the host, as well as comorbidities, certainty of diagnosis, site of infection, and antifungal pharmacological properties, due to the disease's heterogeneity (different types of affected hosts, sites of infection, and infecting Mucorales).

Mariya Samsonova et al. discussed about Pulmonary mucormycosis [10]. Mucormycosis (zygomicosis) is a fungal infection caused by fungus of the Zygomycetes class (order Mucorales). This illness may damage the lungs and has a proclivity for invading blood vessels, which can lead to widespread infection. It's not always easy to figure out what's wrong with you. Although culturing respiratory tract samples is negative in up to 60% of patients, there is no acceptable serologic test to confirm the diagnosis. The radiographic indications of invasive aspergillosis are similar. As a result, identifying hyphae in a lung sample is often used to make a definite diagnosis. The article describes a case of invasive mycosis caused by Zygomycetes. A hospitalized patient with hepatic cirrhosis, acute pancreatic necrosis, secondary diabetes mellitus, hyperglycemia, and hepatocellular insufficiency was identified with this infection. The illness progressed quickly in terms of its clinical course. Cavitation of pulmonary infiltration occurred in the 11th day following presentation, according to a CT scan of the lungs. A bronchial biopsy and immunohistochemistry confirmed the diagnosis of pulmonary fungal infection.

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 11, Nov 2022

3. DISCUSSION

Mucormycosis is a new fungal illness that has a significant morbidity and death rate. Mucormycetes are classified as Mucorales in the Mucoromycotina subphylum. Because of the disease's rarity, large, randomized clinical studies are almost difficult to perform, and the majority of the current data on epidemiology, diagnosis, and therapy comes from case reports and case series. Mucormycosis still has a significant death rate. Antifungal medications are used in conjunction with surgical intervention in the treatment of fungal infections. Isavuconazole is the sole novel medication that has action against Mucorales, although it does not seem to provide substantial benefits over traditional first-line treatment with amphotericin B-based medicines or posaconazole. Mucormycosis, its diagnosis, and treatment are discussed in this article.

4. CONCLUSION

Despite recent improvements in diagnosis and treatment, mucormycosis (MCM) remains a deadly illness with a high death rate. It is caused by filamentous fungus belonging to the Mucorales order of the Zygomycetes class. Although it is typically thought of as an opportunistic infection that affects patients with diabetes mellitus (DM), neutropenia, cancer, chronic renal failure, and acquired immunodeficiency syndrome, as well as those who have had organ or hematopoietic stem cell transplants, it can also affect immunocompetent hosts (such as trauma patients). Mucormycosis (zygomycosis) has emerged as a dangerous illness in a growing number of individuals suffering from chronic and/or severe immunosuppression. To summarize, mucormycosis is a disease that is often aggressive and has a high death rate. However, since the etiopathogenesis of this illness varies across the globe, physicians have a difficult time diagnosing it. However, given the disease's high death rate, I early and quick identification, (ii) recovery from predisposing factors, and (iii) early intervention with surgical debridement and therapeutic medicines are the only options for improving the situation.

REFERENCES:

[1] T. N. Watkins *et al.*, “Inhibition of EGFR signaling protects from mucormycosis,” *MBio*, 2018, doi: 10.1128/mBio.01384-18.

[2] J. R. Francis, P. Villanueva, P. Bryant, and C. C. Blyth, “Mucormycosis in children: Review and recommendations for management,” *Journal of the Pediatric Infectious Diseases Society*. 2018, doi: 10.1093/jpids/pix107.

[3] B. Pilmis, A. Alanio, O. Lortholary, and F. Lanternier, “Recent advances in the understanding and management of mucormycosis,” *F1000Research*, 2018, doi: 10.12688/f1000research.15081.1.

[4] A. D. Castrejón-Pérez, I. Miranda, O. Welsh, E. C. Welsh, and J. Ocampo-Candiani, “Cutaneous mucormycosis,” *An. Bras. Dermatol.*, 2017, doi: 10.1590/abd1806-4841.20176614.

[5] D. E. Corzo-León, L. D. Chora-Hernández, A. P. Rodríguez-Zulueta, and T. J. Walsh, “Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases,” *Med. Mycol.*, 2018, doi: 10.1093/mmy/myx017.

[6] Y. Song *et al.*, “Mucormycosis in renal transplant recipients: Review of 174 reported cases,” *BMC Infect. Dis.*, 2017, doi: 10.1186/s12879-017-2381-1.

[7] D. P. Kontoyiannis *et al.*, “Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: A retrospective study,” *BMC Infect. Dis.*, 2016, doi: 10.1186/s12879-016-2023-z.

[8] A. Skiada, C. Lass-Floerl, N. Klimko, A. Ibrahim, E. Roilides, and G. Petrikkos, “Challenges in the diagnosis and treatment of mucormycosis,” *Medical Mycology*. 2018, doi: 10.1093/mmy/myx101.

[9] N. V. Sipsas, M. N. Gamaletsou, A. Anastasopoulou, and D. P. Kontoyiannis, “Therapy of mucormycosis,” *Journal of Fungi*. 2018, doi: 10.3390/jof4030090.

[10] M. V. Samsonova, A. L. Chernyayev, Y. S. Lebedin, K. Y. Mikhaylichenko, and A. E. Polivanova, "Pulmonary mucormycosis," *Pulmonologiya*, 2018, doi: 10.18093/0869-0189-2018-28-2-243-247.